HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 368 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,937,120 | -3.3% | 155,422 | -8.7% | 0.07% | +4.3% |
| Q2 2023 | $6,139,042 | -14.6% | 170,198 | -9.6% | 0.07% | -17.6% |
| Q1 2023 | $7,186,747 | -34.9% | 188,184 | -3.1% | 0.08% | -38.4% |
| Q4 2022 | $11,045,997 | +45.1% | 194,130 | +0.8% | 0.14% | +34.0% |
| Q3 2022 | $7,615,000 | -15.5% | 192,599 | -5.9% | 0.10% | -10.4% |
| Q2 2022 | $9,009,000 | +76.0% | 204,745 | +59.5% | 0.12% | +113.0% |
| Q1 2022 | $5,120,000 | +1.1% | 128,384 | +1.9% | 0.05% | +5.9% |
| Q4 2021 | $5,064,000 | -0.6% | 125,933 | +0.5% | 0.05% | 0.0% |
| Q3 2021 | $5,097,000 | -5.5% | 125,300 | +5.5% | 0.05% | -3.8% |
| Q2 2021 | $5,393,000 | +12.8% | 118,762 | +3.5% | 0.05% | +6.0% |
| Q1 2021 | $4,783,000 | -5.8% | 114,721 | -3.5% | 0.05% | -13.8% |
| Q4 2020 | $5,079,000 | – | 118,927 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |